Drugs / 4A10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07586618 | Jun 2026 → May 2028 expected | acute lymphoblastic leukemia, lymphoblastic lymphoma | Allterum Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4A10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07586618 ↗ |
| Known as | B4532 | “4A10 (Molecule B4532) is an investigational human Immunoglobulin G Subclass 1 (IgG1) monoclonal antibody that specifically binds CD127 (Interleukin-7 receptor alpha subunit, IL-7Rα).” NCT07586618 ↗ |
| Modality | Monoclonal antibody | “human Immunoglobulin G Subclass 1 (IgG1) monoclonal antibody” NCT07586618 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT07586618 ↗ |